Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AUDIOEYE INCAEYE · Entity 6844 | Director | October 01, 2026 | October 03, 2026 |
| IRADIMED CORPIRMD · Entity 4896 | Director | December 11, 2025 | December 15, 2025 |
| NATUS MEDICAL INCBABY · Entity 125256 | Director · President and CEO | April 30, 2018 | May 02, 2018 |
| OSI SYSTEMS INCOSIS · Entity 4160 | Director | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AUDIOEYE INC
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,684 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,000 · Balance 218,684 F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date.
IRADIMED CORP
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,932 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 1,026 · Balance 1,932 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
NATUS MEDICAL INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 639,257 |
Ending reported balance
After 2018-04-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2018-04-30 · Exercise / conversion · Acquired 47,500 · Balance 686,757 Row 2 · 2018-04-30 · Sale · Disposed 47,500 · Balance 639,257 F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2018-04-30 · Exercise / conversion · Acquired 76,827 · Balance 716,084 Row 4 · 2018-04-30 · Sale · Disposed 76,827 · Balance 639,257 F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2018-04-30 · Exercise / conversion · Acquired 35,673 · Balance 674,930 Row 6 · 2018-04-30 · Sale · Disposed 35,673 · Balance 639,257 F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 112,500 |
Reported balance
After 2018-04-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-04-30 · Exercise / conversion · Disposed 47,500 · Balance 112,500 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 35,673 |
Reported balance
After 2018-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-01 · Exercise / conversion · Disposed 76,827 · Balance 35,673 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 0 |
Reported balance
After 2018-05-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-02 · Exercise / conversion · Disposed 35,673 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
OSI SYSTEMS INC
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,295 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 90 · Balance 5,295 F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Caesars Entertainment, Inc.
Report date July 20, 2020 · Filed July 23, 2020
Section 16 reporting ended · disclosed 2020-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,082 |
Ending reported balance
After 2020-07-20 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2020-07-20 · Exercise / conversion · Acquired 9,256 · Balance 91,256 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 2 · 2020-07-20 · Exercise / conversion · Acquired 17,980 · Balance 109,236 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 3 · 2020-07-20 · Exercise / conversion · Acquired 6,984 · Balance 116,220 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 4 · 2020-07-20 · Exercise / conversion · Acquired 4,612 · Balance 120,832 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 5 · 2020-07-20 · Exercise / conversion · Acquired 4,305 · Balance 125,137 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 6 · 2020-07-20 · Exercise / conversion · Acquired 2,945 · Balance 128,082 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-20 · Exercise / conversion · Disposed 9,256 · Balance 0 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-20 · Exercise / conversion · Disposed 17,980 · Balance 0 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-20 · Exercise / conversion · Disposed 6,984 · Balance 0 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-20 · Exercise / conversion · Disposed 4,612 · Balance 0 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-07-20 · Exercise / conversion · Disposed 4,305 · Balance 0 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-07-20 · Exercise / conversion · Disposed 2,945 · Balance 0 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2019 Filed Jul 9, 2019 01:52 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 1,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-039638 · a4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,635 Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 22:43 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 2,536 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-19-000949 · form4.xml · derivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,536 Underlying: Common Stock · 2,536 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on June 26, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on June 26, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 23:20 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | GrantRestricted Stock Units · Derivative | 4,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005636 · doc4.xml · derivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,305 Underlying: Common Stock · 4,305 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Restricted stock units were granted on January 25, 2019 pursuant to the 2015 Equity Incentive Plan. Reporting person elected to defer vesting until the first to occur of separation of service and a change in control. F2 · derivative.expiration_date: Restricted stock units were granted on January 25, 2019 pursuant to the 2015 Equity Incentive Plan. Reporting person elected to defer vesting until the first to occur of separation of service and a change in control. Read SEC document |
| September 05, 2018 Filed Sep 5, 2018 20:02 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | PurchaseCommon Stock | 1,000 | $46.50 | $46,500.00 |
DisclosureSEC source: 0001209191-18-049505 · doc4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,832 Read SEC document |
| August 07, 2018 Filed Aug 7, 2018 20:30 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | PurchaseCommon Stock | 4,000 | $42.45 | $169,813.60 |
DisclosureSEC source: 0001209191-18-045685 · doc4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,832 Read SEC document |
| July 06, 2018 Filed Jul 11, 2018 00:21 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 2,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009610 · edgar.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,952 Read SEC document |
| May 02, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNonqualified Stock Option · Derivative | 35,673 | $10.69 Strike: $10.69 | $381,344.37 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · derivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,673 shares Expires 2018-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNonqualified Stock Option · Derivative | 76,827 | $10.69 Strike: $10.69 | $821,280.63 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · derivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,673 Underlying: Common Stock · 76,827 shares Expires 2018-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNonqualified Stock Option · Derivative | 47,500 | $10.69 Strike: $10.69 | $507,775.00 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · derivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 160,000 shares Expires 2018-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 35,673 | $33.37 | $1,190,408.01 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,257 F3 · price: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 35,673 | $10.69 | $381,344.37 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 76,827 | $33.51 | $2,574,472.77 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,257 F2 · price: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 76,827 | $10.69 | $821,280.63 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 47,500 | $33.47 | $1,589,825.00 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,257 F1 · price: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:56 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 47,500 | $10.69 | $507,775.00 |
DisclosureSEC source: 0000878526-18-000048 · wf-form4_152529452863883.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 01:41 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | GrantRestricted Stock Unit · Derivative | 4,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-006116 · doc4.xml · derivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,612 Underlying: Common Stock · 4,612 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Restricted stock units were granted on January 26, 2018 pursuant to the 2015 Equity Incentive Plan. Reporting person elected to defer vesting until the first to occur of separation of service and a change in control. F2 · derivative.expiration_date: Restricted stock units were granted on January 26, 2018 pursuant to the 2015 Equity Incentive Plan. Reporting person elected to defer vesting until the first to occur of separation of service and a change in control. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 19:18 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock | 111,300 | $38.20 | $4,251,660.00 |
DisclosureSEC source: 0000878526-18-000004 · wf-form4_151502511185094.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,257 F1 · shares: Restricted Stock Award vest over 4 years from the date of the grant. 50% will vest on the second anniversary of the grant, 25% on the third anniversary of the grant, and 25% on the fourth anniversary of the grant. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 19:18 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock | 40,283 | $38.20 | $1,538,810.60 |
DisclosureSEC source: 0000878526-18-000004 · wf-form4_151502511185094.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,957 Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 23:55 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 2,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011824 · edgar.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,727 Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:58 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock, $0.001 par value per share | 9,783 | $34.15 | $334,089.45 |
DisclosureSEC source: 0000878526-17-000075 · wf-form4_150300350707486.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,240 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 13:53 UTC | NATUS MEDICAL INC BABY · Entity 125256 | PurchaseCommon Stock | 4,000 | $33.98 | $135,900.00 |
DisclosureSEC source: 0000878526-17-000049 · wf-form4_149754921618525.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $33.90 to $34.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2017 Filed May 31, 2017 17:10 UTC | NATUS MEDICAL INC BABY · Entity 125256 | PurchaseCommon Stock | 6,000 | $33.81 | $202,860.00 |
DisclosureSEC source: 0000878526-17-000047 · wf-form4_149626502019484.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $33.78 to $33.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 357 shares purchased pursuant to the Company's Employee Stock Purchase Plan since the date of the reporting persons last Form 4. Read SEC document |
| January 27, 2017 Filed Feb 3, 2017 23:40 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | GrantRestricted Stock Unit · Derivative | 9,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007822 · doc4.xml · derivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,256 Underlying: Common Stock · 9,256 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 27, 2017 pursuant to the 2015 Equity Incentive Plan. The restricted stock units will vest and become non-forfeitable upon the third anniversary of the date of grant, which will be January 27, 2020. The restricted stock units will settle in common stock upon vesting. Unvested restricted stock units will vest upon (x) the termination of employment if such termination is without cause, for good reason, or due to the death or the disability of the reporting person and (y) consummation of a change of control of Eldorado Resorts, Inc. F2 · derivative.expiration_date: The restricted stock units were granted on January 27, 2017 pursuant to the 2015 Equity Incentive Plan. The restricted stock units will vest and become non-forfeitable upon the third anniversary of the date of grant, which will be January 27, 2020. The restricted stock units will settle in common stock upon vesting. Unvested restricted stock units will vest upon (x) the termination of employment if such termination is without cause, for good reason, or due to the death or the disability of the reporting person and (y) consummation of a change of control of Eldorado Resorts, Inc. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 20:10 UTC | NATUS MEDICAL INC BABY · Entity 125256 | GrantCommon Stock | 118,000 | $34.80 | $4,106,400.00 |
DisclosureSEC source: 0000878526-17-000010 · wf-form4_148366503586422.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,666 F1 · shares: Restricted Stock Award vest over 4 years from the date of the grant. 50% will vest on the second anniversary of the grant, 25% on the third anniversary of the grant, and 25% on the fourth anniversary of the grant. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 20:10 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock | 27,730 | $34.80 | $965,004.00 |
DisclosureSEC source: 0000878526-17-000010 · wf-form4_148366503586422.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,666 Read SEC document |
| December 16, 2016 Filed Dec 16, 2016 14:43 UTC | NATUS MEDICAL INC BABY · Entity 125256 | PurchaseCommon Stock | 10,000 | $35.20 | $352,000.00 |
DisclosureSEC source: 0000878526-16-000210 · wf-form4_148191736967464.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,396 Read SEC document |
| November 28, 2016 Filed Nov 28, 2016 17:04 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Tax withholdingCommon Stock | 3,038 | $48.05 | $145,975.90 |
DisclosureSEC source: 0000878526-16-000208 · wf-form4_148037067522690.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,396 F1 · balance_after: Includes 709 shares purchased pursuant to the Company's Employee Stock Purchase Plan since the date of the reporting persons last Form 4. Read SEC document |
| November 08, 2016 Filed Nov 8, 2016 20:38 UTC | Caesars Entertainment, Inc. ERI · Entity 3789 | PurchaseCommon Stock | 10,000 | $10.99 | $109,900.00 |
DisclosureSEC source: 0001179110-16-031322 · edgar.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Read SEC document |
| October 27, 2016 Filed Oct 27, 2016 17:27 UTC | NATUS MEDICAL INC BABY · Entity 125256 | PurchaseCommon Stock | 10,000 | $38.30 | $383,030.00 |
DisclosureSEC source: 0000878526-16-000203 · wf-form4_147760366467217.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,725 F1 · price: This transaction was executed in multiple trades at prices ranging from $38.00 to $38.60. The price reflected above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 28, 2016 Filed Sep 28, 2016 11:06 UTC | NATUS MEDICAL INC BABY · Entity 125256 | PurchaseCommon Stock | 10,000 | $38.48 | $384,840.00 |
DisclosureSEC source: 0000878526-16-000195 · wf-form4_147507514826355.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,725 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.